Reference change values and determinants of variability of NT-proANP and GDF15 in stable chronic heart failure

Basic Research in Cardiology

Volumn 104, Issue 6, 2009, Pages 731-738

  Frankenstein, Lutz ^a   Remppis, Andrew ^a   Frankenstein, Joerdis ^b   Hess, Georg ^c   Zdunek, Dietmar ^d   Gut, Simon ^a   Slottje, Karen ^a   Katus, Hugo A ^a   Zugck, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d Roche Diagnostics Ltd   (Switzerland)

Author keywords

Change; Chronic heart failure; GDF15; NT proANP; Reference change values

Indexed keywords

AMINO TERMINAL PRO ATRIAL NATRIURETIC FACTOR; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; TROPONIN T; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HEART FAILURE; HORMONE DETERMINATION; HUMAN; KIDNEY FUNCTION; MALE; PATIENT ASSESSMENT; REFERENCE VALUE; SYSTOLIC DYSFUNCTION;

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; RISK FACTORS;

EID: 70349652501     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-009-0027-1     Document Type: Article

References (34)

1. Azizi C, Maistre G, Kalotka H, Isnard R, Barthélemy C, Masson F, Pham P, Pousset F, Eurin J, Lechat P, Komajda M, Carayon A (1996) Plasma levels and molecular forms of proatrial natriuretic peptides in healthy subjects and in patients with congestive heart failure. J Endocrinol 148:51-57
2. Berger R, Huelsmann M, Strecker K, Moertl D, Moser P, Bojic A, Pacher R (2005) Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Eur J Clin Invest 35:24-31
3. Brattelid T, Tveit K, Birkeland JA, Sjaastad I, Qvigstad E, Krobert KA, Hussain RI, Skomedal T, Osnes JB, Levy FO (2007) Expression of mRNA encoding G protein-coupled receptors involved in congestive heart failure - a quantitative RT-PCR study and the question of normalisation. Basic Res Cardiol 102:198-208
4. Clerico A, Carlo Zucchelli G, Pilo A, Passino C, Emdin M (2006) Clinical relevance of biological variation: The lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin Chem Lab Med 44(4):366-378
5. Clerico A, Recchia FA, Passino C, Emdin M (2006) Cardiac endocrine function is an essential component of the homeostatic regulation network: Physiological and clinical implications. Am J Physiol Heart Circ Physiol 290:H17-H29
6. Cortes R, Rivera M, Salvador A, Bertomeu V, de Burgos FG, Rosello-Lleti E, Portoles M, Paya R, Martinez-Dolz L, Climent V (2007) Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study. Heart 93:957-962
7. Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. Br Med J 330:625
8. Eda S, Kaufmann J, Roos W, Pohl S (1998) Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal 12:137-144
9. Frankenstein L, Nelles M, Slavutsky M, Schellberg D, Doesch A, Katus H, Remppis A, Zugck C (2007) Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents. J Heart Lung Transplant 26:1033-1039
10. Hogenhuis J, Voors AA, Jaarsma T, Hillege HL, Boomsma F, van Veldhuisen DJ (2005) Influence of age on natriuretic peptides in patients with chronic heart failure: A comparison between ANP/NT-ANP and BNP/ NT-proBNP. Eur J Heart Fail 7:81-86
11. Iglesias N, Petersen PH, Ricós C (2005) Power function of the reference change value in relation to cut-off points, reference intervals and index of individuality. Clin Chem Lab Med 43:441-448
12. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juillière Y (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J Am Coll Cardiol 49:1733-1739
13. Katoh Y, Katoh M (2006) Comparative integromics on BMP/GDF family. Int J Mol Med 17:951-955
14. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC (2006) The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/ reperfusion injury. Circ Res 98:351-360
15. Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, Drexler H, Johnston N, Wallentin L, Wollert KC (2007) Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 53:284-291
16. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC (2007) Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50:1054-1060
17. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN, Val-HeFT Investigators (2007) Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116:1242-1249
18. Laukkanen JA, Kurl S, Ala-Kopsala M, Vuolteenaho O, Ruskoaho H, Nyyssönen K, Salonen JT (2006) Plasma N -terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men. Eur Heart J 27:1230-1237
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470
20. Luchner A, Schunkert H (2004) Interactions between the sympathetic nervous system and the cardiac natriuretic peptide system. Cardiovasc Res 63:443-449
21. Missbichler A, Hawa G, Schmal N, Woloszczuk W (2001) Sandwich ELISA for proANP 1-98 facilitates investigation of left ventricular dysfunction. Eur J Med Res 6:105-111
22. Pedersen EB, Pedersen HB, Jensen KT (1999) Pulsatile secretion of atrial natriuretic peptide and brain natriuretic peptide in healthy humans. Clin Sci (Lond) 97:201-206
23. Petersen PH, Sandberg S, Fraser CG, Goldschmidt H (2001) Influence of index of individuality on false positives in repeated sampling from healthy individuals. Clin Chem Lab Med 39:160-165
24. Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M (2008) Natriuretic peptides: An update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 21:733-741
25. Schou M, Gustafsson F, Kjaer A, Hildebrandt PR (2007) Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 28:177-182
26. Schou M, Gustafsson F, Nielsen PH, Madsen LH, Kjaer A, Hildebrandt PR (2007) Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 9:68-74
27. Stanton E, Hansen M, Wijeysundera HC, Kupchak P, Hall C, Rouleau JL, PRAISE-2 study investigators (2005) A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin. Eur J Heart Fail 7:557-565
28. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ, Task Froce for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology (2005) Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26:1115-1140
29. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000) Treatment of heart failure guided by plasma aminoterminal terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126-1130
30. White M, Rouleau JL, Hall C, Arnold M, Harel F, Sirois P, Greaves S, Solomon S, Ajani U, Glynn R, Hennekens C, Pfeffer M (2001) Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction. Am Heart J 142:1056-1064
31. Wollert KC (2007) Growth-differentiation factor-15 in cardiovascular disease: From bench to bedside, and back. Basic Res Cardiol 102:412-415
32. Wu AH, Smith A (2004) Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 6:355-358
33. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98:342-350
34. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, Sedor FA, Butch AW (2003) Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 338:107-115